AstraZenca Pharma Financial Statements

AstraZenca Pharma (ASTRAZEN) reported revenue of ₹17.57B in FY2025 with net income of ₹1.16B. Total assets stood at ₹15.18B and free cash flow was ₹636.10M.

AstraZenca Pharma Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		8.26B	8.20B	10.29B	13.30B	17.57B
Cost of Rev. Cost of Revenue		-2.95B	-3.12B	-3.60B	-5.95B	-9.63B
Gross Profit		5.31B	5.08B	6.69B	7.36B	7.94B
SGA Sales, General & Admin		-3.80B	-4.07B	-4.78B	-5.17B	-4.99B
Op. Income Operating Income		1.28B	839.83M	1.75B	2.04B	2.55B
PBT Profit Before Tax		1.27B	830.36M	1.34B	2.20B	1.56B
Net Income		933.00M	615.93M	992.93M	1.62B	1.16B
Dil. Shares Diluted Shares		25.00M	25.00M	25.00M	25.00M	25.00M
Diluted EPS		37.32	24.64	39.72	64.60	46.30

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows AstraZenca Pharma's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

AstraZenca Pharma Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		6.19B	7.06B	8.35B	9.33B	13.42B
Non-curr. assets Total non-current assets		1.56B	1.51B	1.49B	1.45B	1.76B
Total assets		7.75B	8.57B	9.85B	10.78B	15.18B
Curr. liabilities Total current liabilities		3.04B	3.33B	3.84B	3.57B	7.03B
Non-curr. liab. Total non-current liabilities		150.40M	125.20M	122.50M	89.90M	447.70M
Total liabilities		3.19B	3.45B	3.96B	3.66B	7.48B
Total equity		4.56B	5.11B	5.89B	7.12B	7.70B
Total liab. & eq. Total liabilities & equity		7.75B	8.57B	9.85B	10.78B	15.18B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures AstraZenca Pharma's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

AstraZenca Pharma Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		1.27B	830.40M	1.34B	2.20B	1.56B
Operating CF Cash flow Operating Activities		1.05B	1.01B	582.90M	278.70M	653.60M
Capex Investments in PPE		-77.10M	-96.20M	-85.20M	-107.60M	-17.50M
Investing CF Cash flow Investing Activities		1.73B	47.40M	181.10M	217.40M	308.00M
Dividend Paid		-50.00M	-50.00M	-200.00M	-400.00M	-600.00M
Financing CF Cash flow Financing Activities		-89.70M	-94.60M	-244.80M	-443.80M	-655.90M
Cash (start) Cash at beginning of period		835.00M	3.52B	4.48B	5.00B	5.06B
Cash (end) Cash at end of period		3.52B	4.48B	5.00B	5.06B	5.36B
FCF Free Cash Flow		970.70M	911.80M	497.70M	171.10M	636.10M

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how AstraZenca Pharma's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025